BioRestorative Therapies (BRTX) Accounts Payables (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Accounts Payables came in at $1.3 million in Q4 2025, up 177.7% YoY from $483070.0 in Q4 2024, and up 56.01% on a QoQ basis from $859898.0 in Q3 2025.
BioRestorative Therapies (BRTX) Accounts Payables (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Accounts Payables data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Accounts Payables rose 177.7% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (up 177.7% YoY) and the FY2025 annual result came in at $1.3 million, up 177.7% from the prior year.
- Accounts Payables rose to $1.3 million in Q4 2025, from $859898.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $1.3 million in Q4 2025 to a low of $50827.0 in Q4 2021.
- A 5-year average of $363887.0 and a median of $238281.5 in 2021 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2021 — Accounts Payables plunged 88.01% — and 2022, when it jumped 287.17%.
- Tracing BRTX's Accounts Payables over 5 years: stood at $50827.0 in 2021, then jumped by 236.24% to $170902.0 in 2022, then gained by 10.82% to $189389.0 in 2023, then soared by 155.07% to $483070.0 in 2024, then surged by 177.7% to $1.3 million in 2025.
- The last three Accounts Payables figures came in at $1.3 million (Q4 2025), $859898.0 (Q3 2025), and $609931.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | BioRestorative Therapies | 1.94 Mn | -1.02 Mn | 17,964.00 | 1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.34 Mn |
| Sep 30, 2025 | 859,898.00 |
| Jun 30, 2025 | 609,931.00 |
| Mar 31, 2025 | 599,500.00 |
| Dec 31, 2024 | 483,070.00 |
| Sep 30, 2024 | 401,379.00 |
| Jun 30, 2024 | 215,920.00 |
| Mar 31, 2024 | 230,902.00 |
| Dec 31, 2023 | 189,389.00 |
| Sep 30, 2023 | 227,355.00 |
| Jun 30, 2023 | 276,048.00 |
| Mar 31, 2023 | 92,586.00 |
| Dec 31, 2022 | 170,902.00 |
| Sep 30, 2022 | 468,501.00 |
| Jun 30, 2022 | 378,233.00 |
| Mar 31, 2022 | 213,893.00 |
| Dec 31, 2021 | 50,827.00 |
| Sep 30, 2021 | 124,558.00 |
| Jun 30, 2021 | 97,692.00 |
| Mar 31, 2021 | 245,661.00 |